The Comparative Analysis of Different Formulations of PCV and Its Effect on Immune Response after Prophylactic Administration of Antipyretic in Pediatrics

Abstract

BACKGROUND INFORMATION: Streptococcus pneumoniae is the leading bacterial pathogen in children, particularly in infants and young children. Can cause lobar pneumonia (affecting one or more lung lobes) or bronchopneumonia (patchy areas in both lungs). Vaccination is a simple, safe, and effective way of protecting people against harmful diseases before they come into contact with them. It uses the body's natural defenses to build resistance to specific infections and makes the immune system stronger. Vaccine adherence in the children and reporting immune responses and counseling about the missed dose schedules.

MATERIALS AND METHODS: A descriptive research approach with a nonexperimental design was adopted for the study. a total of 144 children with immunization schedules who met with inclusion criteria were selected. All the immunization charts of the children were monitored and noted. The most preferred vaccine for the children was compared based on their availability and cost-effectiveness. Immune responses were reported by communicating with the caretakers any missed dose schedules by the children were informed about the benefits of vaccine adherence to avoid the complications associated with the pneumococcal infection.

RESULTS: The study represented about the pneumococcal conjugate vaccine indicates that older children > (0-6 months) are more likely to have missed doses compared to younger age groups < (0-6), the gender distribution of the participants is 49.3% of the participants are female, and 50.7% are male. Vaccine preferred shows the majority of children, 56.9% received the Synflorix vaccine. Vaccines are preferred based on mostly their availability 67%, followed by cost-effectiveness 47% and side effects. PCV successfully induced an immune response in a substantial proportion of individuals (72.9%) and (27.1%) did not. Mostly Pain 56.3%, fever 55.6%, erythema 43.8%, followed by itching 29.9% are the immune responses. Prophylactic treatment Antipyretic suggests that 64.6% of individuals receive it to prevent fever. Missed doses (52.1%) of the children completed their PCV schedule without missing any doses and 47.9% of children not. Irritability for more than 24 hours is seen in 27.8% of children. Counseling regarding given and missed doses was received by 94.4%, while only 5.6% did not.

CONCLUSION: The findings from this study underscore the importance of a multifaceted approach to improving pneumococcal conjugate vaccine coverage. Addressing the safety profile and reactogenicity of PCV formulations, optimizing deployment strategies, ensuring effective use of prophylactic antipyretics, enhancing parental knowledge, and addressing barriers to vaccine adherence is crucial for improving vaccination rates. Future research should continue to explore these areas, focusing on the development of strategies to mitigate side effects, optimize vaccine delivery, prevalence of missing dosing schedules, more focus on missing the booster dose, and enhance parental education through counseling. By addressing these factors, we can work towards achieving higher vaccine coverage and better protection against pneumococcal disease.